Johnson & Johnson Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Johnson & Johnson (JNJ) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 1.89 million shares for the 12-month period ending 2012-01-01, per its 10-K filed 2012-02-23.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2012-02-23
- Johnson & Johnson share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2012 was 1.89M shares, a 17.86% decline from fiscal 2011.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2011 was 2.30M shares, a 64.94% increase from fiscal 2010.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2010 was 1.39M shares.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2008 was -1.47M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month as first filed |
|---|---|---|
| 2012-01-01 | 1.89M shares 10-K · filed 2012-02-23 | |
| 2011-01-02 | 2.30M shares 10-K · filed 2012-02-23 | -2.30M shares 10-K · filed 2011-02-25 |
| 2010-01-03 | 1.39M shares 10-K · filed 2012-02-23 | -1.39M shares 10-K · filed 2011-02-25 |
| 2008-12-28 | -1.47M shares 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |